Tick Saliva Drug May Help Reduce HIV-Linked Heart Disease Risk

An experimental drug made from tick saliva may hold promise as a potential treatment for reducing HIV-linked heart disease risk.

Tick saliva drug may hold promise as a potential treatment for reducing HIV-linked heart disease risk, said by the researchers at the University of Pittsburgh Center for Vaccine Research and National Institutes of Health.

The increased heart disease risk is driven by a subset of immune cells in people with HIV which continue to express a protein that triggers blood clotting and inflammation even after the HIV virus is under control by medication, the scientists explain in today's issue of Science Translational Medicine.

Parliament Passes HIV and AIDS Bill
The HIV and AIDS Bill 2017 passed by the Parliament strengthens rights of patients living with HIV and cracks down on discrimination.

‘Tick saliva treatment has the potential to improve the clinical management of HIV-infected patients and help them to live longer and healthier.’

Furthermore, the researchers found that Ixolaris, an experimental drug isolated from tick saliva and previously tested to treat blood clots in animals, successfully reduced the inflammation in monkeys infected with SIV, the primate form of HIV.

"People are living long, fruitful lives with HIV thanks to tremendous strides in antiviral treatment regimens, however those lives are being cut short due to perplexingly high rates of heart disease," said co-senior author Ivona Pandrea, M.D., Ph.D., professor of pathology in Pitt's Center for Vaccine Research.

"By uncovering one of the cellular mechanisms driving the heart disease, we can look for medications--such as Ixolaris--that specifically target and disrupt that mechanism."

HIV Diagnozed Pregnant Women Twice Likely at Risk For Domestic Violence
Intimate partner violence affects both women and children during and after pregnancy. HIV positive women are twice likely at risk of domestic violence after pregnancy.

Co-senior author Irini Sereti, M.D., of the NIH's National Institute of Allergy and Infectious Diseases (NIAID), tested blood samples from people without HIV, people with HIV whose infections were well-controlled by antiretroviral therapy and people with HIV who weren't on the medications.

The researchers found an elevated number of immune cells called monocytes that expressed high levels of the 'tissue factor' protein, which is associated with blood clotting and other inflammatory proteins, in the blood from people with HIV, regardless of how well their infection was controlled.

Offering HIV Test at new GP Can Aid Early Diagnosis
HIV screening is cost effective and potentially cost saving. GP-based testing for HIV is cost-effective and should be rolled out in local authorities.

These findings were confirmed by Pandrea and her team in monkeys that progress to AIDS after infection with SIV. The same cells isolated from a different species of monkey that usually does not develop heart disease when infected with SIV do not produce tissue factor, thus reinforcing the role of this damaging protein in triggering cardiovascular disease in the HIV/SIV settings.

The scientists then exposed the human blood samples to Ixolaris and observed that the drug blocked the activity of tissue factor. When tested in a small group of monkeys during early SIV infection, the treatment significantly lowered the levels of inflammatory proteins linked to cardiovascular disease.

A Step Forward in HIV Vaccine Efficacy
The efficacy of the HIV vaccine can be improved by changing its route of administration and the interval between doses, suggested a new study.

NIH holds the patent for Ixolaris, which is a small molecule found in the saliva of the tick Ixodes scapularis--commonly known as the deer or blacklegged tick--and was uncovered by study co-author Ivo M. B. Francischetti, M.D., Ph.D., of NIAID.

More studies are needed to test the drug's safety and interaction with other drugs that are used for HIV patients. Ixolaris has not been tested in humans and the results could differ, the researchers also cautioned.

"This treatment has the potential to improve the clinical management of HIV-infected patients and help them to live longer, healthier lives with HIV," said Pandrea. "That, and other therapies that may arise from targeting the inflammation pathway we discovered, are exciting avenues for future research."

Source-Eurekalert